Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients -: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study

被引:98
|
作者
Okin, PM
Jern, S
Devereux, RB
Kjeldsen, SE
Dahlöf, B
机构
[1] Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY 10021 USA
[2] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[3] Ullevaal Univ Hosp, Oslo, Norway
关键词
blood pressure; electrocardiography; hypertrophy; obesity;
D O I
10.1161/01.HYP.35.1.13
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Obesity may limit sensitivity of ECG voltage criteria for left ventricular hypertrophy (LVH) because of the attenuating effects of increased body mass on precordial voltages. However, obesity is associated with an increased prevalence of anatomic LVH, making more accurate ECG criteria in obese patients a clinical priority. ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Clinical and ECG data were available in 8417 patients (54% women; mean age, 67+/-7 years); 2519 were overweight and 1573 were obese by gender-specific body mass index criteria. Increased body mass index had significant but directionally opposite effects on ECG LVH by these 2 criteria. Compared with normal-weight patients, obese and overweight patients had lower Sokolow-Lyon voltage and a lower prevalence of ECG LVH by Sokolow-Lyon criteria (10.9% versus 16.2% versus 31.4%; P<0.001). In contrast, obese and overweight patients had higher mean values of the Cornell product and higher prevalences of ECG LVH by this criterion (75.1% versus 69.9% versus 60.7%; P<0.001). After adjustment for age, gender, race, myocardial infarction, and diastolic and pulse pressure with the use of logistic regression analysis, increased body mass remained highly predictive of the presence of ECG LVH. Compared with normal-weight patients, obese patients had a >2-fold higher risk of ECG LVH by the Cornell product but a 4-fold lower risk of ECG LVH by Sokolow-Lyon voltage; overweight status was associated with intermediate risks, with a 151% greater likelihood of ECG LVH by the Cornell product but only 44% of the risk of LVH by Sokolow-Lyon voltage criteria compared with normal-weight individuals. Thus, Sokolow-Lyon voltage criteria underestimate the prevalence of anatomic LVH in the presence of obesity, whereas Cornell product criteria for ECG LVH appear to provide a more accurate measure of LVH in obese and overweight patients.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [1] Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients -: The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study
    Okin, PM
    Devereux, RB
    Jern, S
    Kjeldsen, SE
    Julius, S
    Dahlöf, B
    [J]. HYPERTENSION, 2000, 36 (05) : 766 - 773
  • [2] Regression of electrocardiographic left ventricular hypertrophy by Losartan versus atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
    Okin, PM
    Devereux, RB
    Jern, S
    Kjeldsen, SE
    Julius, S
    Nieminen, MS
    Snapinn, S
    Harris, KE
    Aurup, P
    Edelman, JM
    Dahlöf, B
    [J]. CIRCULATION, 2003, 108 (06) : 684 - 690
  • [3] Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study
    Devereux, RB
    Lyle, PA
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (11) : 2311 - 2320
  • [4] Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy -: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Gerdts, E
    Oikarinen, L
    Palmieri, V
    Otterstad, JE
    Wachtell, K
    Boman, K
    Dahlöf, B
    Devereux, RB
    [J]. HYPERTENSION, 2002, 39 (03) : 739 - 743
  • [5] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    Devereux, RB
    Dahlöf, B
    Gerdts, E
    Boman, K
    Nieminen, MS
    Papademetriou, V
    Rokkedal, J
    Harris, KE
    Edelman, JM
    Wachtell, K
    [J]. CIRCULATION, 2004, 110 (11) : 1456 - 1462
  • [6] Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study
    Olsen, Michael Hecht
    Wachtell, Kristian
    Beevers, Gareth
    Dahlof, Bjorn
    Devereux, Richard B.
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hams
    Kjeldsen, Sverre E.
    Lederhalle-Pedersen, Ole
    Lindholm, Lars H.
    Narayan, Puneet
    Nieminen, Markku S.
    Omvik, Per
    Opard, Suzanne
    Wedel, Hans
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (01) : 177 - 184
  • [7] Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients:: The Losartan Intervention For Endpoint Reduction (LIFE) study
    Oikarinen, L
    Nieminen, MS
    Toivonen, L
    Viitasalo, M
    Wachtell, K
    Papademetriou, V
    Jern, S
    Dahlöf, B
    Devereux, RB
    Okin, PM
    [J]. AMERICAN HEART JOURNAL, 2003, 145 (05) : 919 - 925
  • [8] Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
    Kjeldsen, Sverre E.
    Devereux, Richard B.
    Hille, Darcy A.
    Lyle, Paulette A.
    Dahlof, Bjorn
    Julius, Stevo
    Edelman, Jonathan M.
    Snapinn, Steven M.
    De Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Lederballe-Pedersen, Ole
    Lindholm, Lars H.
    Nieminen, Markku S.
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    [J]. BLOOD PRESSURE, 2009, 18 (06) : 348 - 361
  • [9] Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
    Olsen, Michael Hecht
    Wachtell, Kristian
    Beevers, Gareth
    Dahlof, Bjorn
    de Simone, Giovanni
    Devereux, Richard B.
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Kjeldsen, Sverre E.
    Lederballe-Pedersen, Ole
    Lindholm, Lars H.
    Lyle, Paulette A.
    Nieminen, Markku S.
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    [J]. JOURNAL OF HYPERTENSION, 2009, 27 (03) : 567 - 574
  • [10] Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy
    Devereux, Richard B.
    de Faire, Ulf
    Fyhrquist, Frej
    Harris, Katherine E.
    Ibsen, Hans
    Kjeldsen, Sverre E.
    Lederballe-Pedersen, Ole
    Lindholm, Lars H.
    Nieminen, Markku S.
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    Hille, Darcy A.
    Dahlof, Bjorn
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (02) : 259 - 270